MR Imaging Biomarker for the Characterization of dynamic metabolic processes in patients with aberrant glucose and/or neurotransmitter metabolism

Medizinische Universität Wien0 个研究点目标入组 60 人开始时间: 2023年1月31日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Brain tumor patients:
•(glucose-avid brain lesions: 5 with cerebral metastases, 5 with lymphomas, 10 high-grade gliomas according to the updated WHO classification 2021) with a Karnofsky performance status =70% who received a routine MRI protocol at 3 T including contrast medium -enhancing agents within two weeks prior to the first study-related measurement but before any biopsy, resection, or radiosurgery occurred. For this pilot study, the group of patients with brain metastases will include distant metastases of all types of primary tumors)
•Epilepsy patients:
•(Clearly defined epileptogenic lesions in MRI such as malformations of cortical development, vascular malformations, scars, etc., routine clinical examinations including long-term video EEG monitoring, FDG-PET, routine clinical T1/T2-weighted MRI)

•MRI inclusion and exclusion criteria:
•- Exclusion of pregnancy
•- Exclusion of nursing mothers
•- Anamnestic exclusion of a metal implantation (pacemaker, metal heart valves, surgical clips, implanted electronic infusion pumps, tattoos and the like).
•- Exclusion of a contrast medium allergy
•- Anamnestic exclusion of claustrophobia
•- Exclude recent head/brain surgery
•- Exclusion of a metabolic disorder (HbA1c>6%)

发起方